Products
Innovative Therapies for Complex Diseases
Repligen's Development Pipeline
Repligen is developing a pipeline of innovative products and therapies with the potential to make a significant impact in the lives of patients suffering from diseases with limited treatment options. The company's diverse pipeline includes the following development programs:
- SecreFlo(TM), synthetic human secretin, positive Phase 3 study completed to improve magnetic resonance imaging of the pancreas
- SecreFlo(TM), synthetic human secretin, investigator led pilot studies to improve pancreatic cancer detection
- RG3039, promoters of SMN2 gene expression, entering Phase 1 for spinal muscual atrophy
- RG2833, HDAC (Class 1) inhibitors, in preclinical development for Friedreich's ataxia
A Trusted Supplier of Life Science Tools
Repligen's Bioprocessing Business
For over 20 years, Repligen's products have played a central role in the successful development and commercial production of biotherapeutic and diagnostic antibodies. Repligen's commitment to quality, depth of technical knowledge and track record for reliability make us the ideal partner to help meet the challenges facing the industry as it strives for biotherapeutic manufacturing industrialization. Repligen is leveraging its knowledge and expertise to provide new products that will enable more efficient, optimized and cost effective processes. Repligen's Bioprocessing division is estimated to record approximately $15.0 million of product revenue in fiscal year 2011 (ended March 31, 2011) and bioprocessing product revenues are currently forecast to increase 10-20% this next year.
Learn more about Repligen’s Bioprocessing Business.